世界中医药2018，Vol.13Issue(8)：1883-1886,1890,5.DOI:10.3969/j.issn.1673-7202.2018.08.016
参一胶囊联合吉非替尼对晚期非小细胞肺癌患者外周血清基质金属蛋白酶-9的影响
Effects of Shenyi Capsule Combined with Gefitinib on Peripheral Serum MMP-9 in Patients with Advanced Non-small Cell Lung Cancer
摘要
Abstract
Objective:To observe the effecta of Shenyi capsule combined with gefitinib on serum MMP-9 in patients with advanced non-small cell lung cancer.Methods:A total of 126 NSCLC patients admitted to our hospital from March 2015 to January 2017 were randomly divided into observation group (Shenyi capsule +gefitinib) and control group (gefitinib Nigeria).After 60 days of treatment, the clinical efficacy of the two groups were compared , and the changes of serum MMP-9 and TIMP-1, the quality of life ( QOL) before and after treatment were compared.Based on the WHO classification of common toxicity of chemotherapy drugs , the occurrence of patients and drug-related serious adverse reactions ( III, IV) were recorded.Results:The total remission rate was 63.93%in the observation group and 55.74%in the control group.There was no significant difference between the two groups (P＞0.05).After treatment, the expression of MMP-9 in the observation group and the control group decreased significantly , while the expression of MMP-9 in the observation group was lower than that in the control group ( P＜0.05).There was no significant change in the expression of TIMP-1 in the observation group, but TIMP-1 expression was increased in the control group ( P＜0.05).After treatment, the QOL scores decreased in both groups , with significant difference (P＜0.05).The QOL score in obser-vation group decreased more than that in control group (P＜0.05).The incidence of adverse reactions in the observation group was 9.84%and in the control group was 24.59%.The incidence of adverse reactions in the observation group was lower than that in the control group (P＜0.05).Conclusion:Adding Shenyi Capsule to gefitinib in patients with advanced non-small cell lung cancer can reduce adverse reactions caused by chemotherapeutic drugs , improve patients′quality of life and reduce the serum MMP-9 ex-pression, which can help to delay the invasion and metastasis of tumor cells.关键词
参一胶囊/吉非替尼/晚期/非小细胞肺癌/基质金属蛋白酶-9Key words
Shenyi capsule/Gefitinib/Advanced/Non-small cell lung cancer/MMP-9分类
医药卫生引用本文复制引用
姜振蕊,李泉星,曲霞..参一胶囊联合吉非替尼对晚期非小细胞肺癌患者外周血清基质金属蛋白酶-9的影响[J].世界中医药,2018,13(8):1883-1886,1890,5.基金项目
山东省高等学校科技计划项目(J15LK02) （J15LK02）
